Differential proteome and phosphoproteome signatures in human T-lymphoblast cells induced by sirolimus

Cell Proliferation

Volumn 43, Issue 4, 2010, Pages 396-404

  Schultze, F C ^a   Petrova, D T ^a   Oellerich, M ^a   Armstrong, V W ^a   Asif, A R ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOPROTEOME; PROTEOME; RAPAMYCIN; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; DRUG INHIBITION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; T LYMPHOBLAST;

CELL PROLIFERATION; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOME; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 77954269416     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/j.1365-2184.2010.00690.x     Document Type: Article

References (35)

1. Vezina C, Kudelski A, Sehgal SN (1975) Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing Streptomycete and isolation of the active principle. J. Antibiot. (Tokyo) 28, 721 726.
2. Panwalkar A, Verstovsek S, Giles FJ (2004) Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 100, 657 666.
3. Morath C, Arns W, Schwenger V, Mehrabi A, Fonouni H, Schmidt J et al. (2007) Sirolimus in renal transplantation. Nephrol. Dial. Transplant. 22, viii61 viii65.
4. Rensing BJ, Vos J, Smits PC, Foley DP, van den Brand MJ, van der Giessen WJ et al. (2001) Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur. Heart J. 22, 2125 2130.
5. Rao RD, Buckner JC, Sarkaria JN (2004) Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Curr. Cancer Drug Targets 4, 621 635.
6. Sehgal SN (2003) Sirolimus: its discovery, biological properties, and mechanism of action. Transplant. Proc. 35, 7S 14S.
7. Christians U, Schmitz V, Schöning W, Bendrick-Peart J, Klawitter J, Haschke M et al. (2008) Toxicodynamic therapeutic drug monitoring of immunosuppressants: promises, reality, and challenges. Ther. Drug Monit. 30, 151 158.
8. Ponticelli C (2004) The pleiotropic effects of mTor inhibitors. J. Nephrol. 17, 762 768.
9. Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH (2005) Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res. 65, 2755 2760.
10. Jacinto E, Hall MN (2003) Tor signalling in bugs, brain and brawn. Nat. Rev. Mol. Cell Biol. 4, 117 126.
11. Bandhakavi S, Xie H, O'Callaghan B, Sakurai H, Kim DH, Griffin TJ (2008) Hsf1 activation inhibits rapamycin resistance and TOR signaling in yeast revealed by combined proteomic and genetic analysis. PLoS One 3, e1598.
12. Dowling RJ, Pollak M, Sonenberg N (2009) Current status and challenges associated with targeting mTOR for cancer therapy. BioDrugs 23, 77 91.
13. Teachey DT, Grupp SA, Brown VI (2009) Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br. J. Haematol. 145, 569 580.
14. Zhao XF, Gartenhaus RB (2009) Phospho-p70S6K and cdc2/cdk1 as therapeutic targets for diffuse large B-cell lymphoma. Expert Opin. Ther. Targets 13, 1085 1093.
15. Choudhary J, Grant SGN (2004) Proteomics in postgenomic neuroscience: the end of the beginning. Nat. Neurosci. 7, 440 445.
16. Robinson JM, Ackerman WE, Kniss DA, Takizawa T, Vandré DD (2008) Proteomics of the human placenta: promises and realities. Placenta 29, 135 143.
17. Huang J, Zhu H, Haggarty SJ, Spring DR, Hwang H, Jin F et al. (2004) Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips. Proc. Natl. Acad. Sci. U.S.A. 101, 16594 16599.
18. Heller T, Asif AR, Petrova DT, Doncheva Y, Wieland E, Oellerich M et al. (2009) Differential proteomic analysis of lymphocytes treated with mycophenolic acid reveals caspase 3-induced cleavage of rho GDP dissociation inhibitor 2. Ther. Drug Monit. 31, 211 217.
19. Asif AR, Armstrong VW, Voland A, Wieland E, Oellerich M, Shipkova M (2007) Proteins identified as targets of the acyl glucuronide metabolite of mycophenolic acid in kidney tissue from mycophenolate mofetil treated rats. Biochimie 89, 393 402.
20. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal. Biochem. 72, 248 254.
21. Gorg A, Obermaier C, Boguth G, Harder A, Scheibe B, Wildgruber R et al. (2000) The current state of two-dimensional electrophoresis with immobilized ph gradients. Electrophoresis 21, 1037 1053.
22. Blum H, Beier H, Gross HJ (1987) Improved silver staining of plant proteins, RNA and DNA in polyacrylamide gels. Electrophoresis 8, 93 99.
23. Shevchenko A, Wilm M, Vorm O, Mann M (1996) Mass spectrometric sequencing of proteins from silver-stained polyacrylamide gels. Anal. Chem. 68, 850 858.
24. Asif AR, Oellerich M, Armstrong VW, Hecker M, Cattaruzza M (2009) T-786C Polymorphism of the NOS-3 gene and the endothelial cell response to fluid shear stress-a proteome analysis. J. Proteome Res. 8, 3161 3168.
25. Luhn S, Berth M, Hecker M, Bernhardt J (2003) Using standard positions and image fusion to create proteome maps from collections of two-dimensional gel electrophoresis images. Proteomics 3, 1117 1127.
26. Chatr-aryamontri A, Ceol A, Palazzi LM, Nardelli G, Schneider MV, Castagnoli L et al. (2007) MINT: the Molecular INTeraction database. Nucleic Acids Res. 35, D572 D574.
27. Ogihara T, Isobe T, Ichimura T, Taoka M, Funaki M, Sakoda H et al. (1997) 14-3-3 protein binds to insulin receptor substrate-1, one of the binding sites of which is in the phosphotyrosine binding domain. J. Biol. Chem. 272, 25267 25274.
28. Leffers H, Madsen P, Rasmussen HH, Honore B, Andersen AH, Walbum E et al. (1993) Molecular cloning and expression of the transformation sensitive epithelial marker stratifin: a member of a protein family that has been involved in the protein kinase C signalling pathway. J. Mol. Biol. 231, 982 998.
29. Powell DW, Rane MJ, Chen Q, Singh S, McLeish KR (2002) Identification of 14-3-3-zeta as a protein kinase B/Akt substrate. J. Biol. Chem. 277, 21639 21642.
30. Tian Q, Feetham MC, Tao WA, He XC, Li L, Aebersold R et al. (2004) Proteomic analysis identifies that 14-3-3-zeta interacts with beta-catenin and facilitates its activation by Akt. Proc. Nat. Acad. Sci. U.S.A. 101, 15370 15375.
31. Cala SE (2000) GRP94 hyperglycosylation and phosphorylation in Sf21 cells. Biochim. Biophys. Acta 1496, 296 310.
32. Csermely P, Miyata Y, Schnaider T, Yahara I (1995) Autophosphorylation of grp94 (endoplasmin). J. Biol. Chem. 270, 6381 6388.
33. Frasson M, Vitadello M, Brunati AM, La Rocca N, Tibaldi E, Pinna LA et al. (2009) Grp94 is Tyr-phosphorylated by Fyn in the lumen of the endoplasmic reticulum and translocates to Golgi in differentiating myoblasts. Biochim. Biophys. Acta 1793, 239 252.
34. Barati MT, Rane MJ, Klein JB, McLeish KR (2006) A proteomic screen identified stress-induced chaperone proteins as targets of Akt phosphorylation in mesangial cells. J. Proteome Res. 5, 1636 1646.
35. Grolleau A, Bowman J, Pradet-Balade B, Puravs E, Hanash S, Garcia-Sanz JA et al. (2002) Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics. J. Biol. Chem. 277, 22175 22184.